It’s been a crucial week for ABIOMED, Inc. (NASDAQ:ABMD); here’s what analysts have to say.

Investors sentiment increased to 1.22 in 2018 Q4. Its up 0.01, from 1.21 in 2018Q3. It increased, as 48 investors sold ABIOMED, Inc. shares while 129 reduced holdings. 62 funds opened positions while 154 raised stakes. 41.23 million shares or 15.03% more from 35.84 million shares in 2018Q3 were reported.
Fincl Advisers Ltd Llc reported 820 shares. Ledyard Bankshares reported 50 shares stake. Utah Retirement reported 7,900 shares. Metropolitan Life Insurance New York holds 8,599 shares or 0.06% of its portfolio. Ing Groep Nv invested 0.04% in ABIOMED, Inc. (NASDAQ:ABMD). Tiverton Asset Management Ltd Co reported 637 shares. Livforsakringsbolaget Skandia Omsesidigt has invested 0.02% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Mitsubishi Ufj Tru Banking stated it has 145,944 shares or 0.2% of all its holdings. Blair William & Com Il stated it has 0.56% in ABIOMED, Inc. (NASDAQ:ABMD). Tekla Mngmt Limited Liability, Massachusetts-based fund reported 12,350 shares. Moreover, Kbc Group Nv has 0.08% invested in ABIOMED, Inc. (NASDAQ:ABMD). Bbva Compass Bank & Trust Incorporated reported 1,417 shares. First Allied Advisory Services has 1,277 shares. 10,845 were accumulated by Jane Street Group Inc. 37,090 were reported by Chevy Chase Tru Holdings Inc.

Since September 24, 2018, it had 0 insider buys, and 5 selling transactions for $32.57 million activity. Howley Michael G sold $4.33 million worth of stock. $8.44M worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by Weber David M. 5,000 shares were sold by Greenfield Andrew J, worth $2.10M.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 2 analysts covering Abiomed (NASDAQ:ABMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abiomed had 5 analyst reports since October 11, 2018 according to SRatingsIntel. The rating was upgraded by Morgan Stanley to “Overweight” on Wednesday, November 7. As per Friday, November 2, the company rating was upgraded by BTIG Research. The firm earned “Equal-Weight” rating on Thursday, October 11 by Morgan Stanley. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Overweight” rating by Morgan Stanley on Wednesday, January 2. Below is a list of ABIOMED, Inc. (NASDAQ:ABMD) latest ratings and price target changes.

08/03/2019 Broker: BidaskScore Rating: Sell Downgrade
02/01/2019 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $496 New Target: $461 Maintain
07/11/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight New Target: $496 Upgrade
02/11/2018 Broker: BTIG Research Old Rating: Neutral New Rating: Buy New Target: $450 Upgrade
11/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $370 New Target: $396 Maintain

The stock increased 2.34% or $7.62 during the last trading session, reaching $333.23. About 372,041 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 27.28% since March 17, 2018 and is uptrending. It has outperformed by 22.91% the S&P500.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $15.02 billion. It also provides continuum of care to heart failure patients. It has a 69.31 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: which released: “Friday Sector Leaders: Healthcare, Energy – Nasdaq” on March 01, 2019, also with their article: “ResMed’s New Brightree Suite to Boost Home Infusion Business – Nasdaq” published on March 08, 2019, published: “Here’s Why Investors Should Bet on Merit Medical (MMSI) Now – Nasdaq” on March 08, 2019. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: and their article: “Cooper Companies (COO) Hits 52-Week High on Solid Prospects – Nasdaq” published on March 07, 2019 as well as‘s news article titled: “Medtronic Gets FDA Approval for Accurian RF Ablation Platform – Nasdaq” with publication date: March 01, 2019.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.